TG Therapeutics, Inc. reported a total revenue of $141.1 million in the second quarter of 2025, with BRIUMVI U.S. net revenue reaching $138.8 million. The company raised its full-year BRIUMVI U.S. net revenue target to approximately $570 – $575 million. A conference call is scheduled for August 4, 2025, at 8:30 AM ET.
BRIUMVI U.S. net product revenue saw significant growth, reaching $138.8 million in Q2 2025. The drug has been approved in the European Union, United Kingdom, Switzerland, and Australia. TG Therapeutics also published two articles in medical journals showcasing the effectiveness of the drug in treating multiple sclerosis.
TG Therapeutics achieved pipeline development goals by enrolling patients in Phase 3 trials for different dosing regimens of BRIUMVI. Financially, the company raised its full-year BRIUMVI U.S. net product revenue target to $570 – $575 million and total global revenue target to approximately $585 million for 2025.
In the second quarter of 2025, TG Therapeutics reported a net income of $28.2 million, with cash, cash equivalents, and investment securities totaling $278.9 million as of June 30, 2025. The company expects its financial position to be sufficient to fund its operations based on current projections. TG Therapeutics will host a conference call today at 8:30 AM ET to discuss their second-quarter financial results. To participate, call 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.) with Conference Title: TG Therapeutics. Audio webcast available on the company’s website. BRIUMVI is a monoclonal antibody for RMS treatment, targeting CD20-expressing B-cells. It is glycoengineered for efficient B-cell depletion at low doses. Authorized specialty distributors listed on www.briumvi.com. Safety information includes contraindications, warnings about infusion reactions, infections, HBV reactivation, PML, and vaccination precautions. Fetal risk may occur when administered to pregnant women. BRIUMVI, a new treatment for multiple sclerosis, requires a pregnancy test before each infusion for women of reproductive age. Reduced immunoglobulins and common adverse reactions like infusion reactions are noted. For more information on BRIUMVI, visit the official website. BRIUMVI Patient Support is offered in the U.S. for those undergoing treatment. Multiple Sclerosis (MS) is a chronic disease affecting the central nervous system with around 1 million cases in the U.S. TG Therapeutics focuses on B-cell disease treatments and has received FDA approval for BRIUMVI in MS treatment. The company has a research pipeline and is dedicated to developing novel therapies. TG Therapeutics, Inc. released statements cautioning investors on factors impacting actual results. Statements included expectations for BRIUMVI’s commercialization and success, revenue projections, and future pipeline programs. Factors include regulatory approvals, market variations, manufacturing, and clinical trial success. Financial data for 2025 showed revenue growth and net income of $28.187 million.
Read more at GlobeNewswire.: TG Therapeutics Reports Second Quarter 2025 Financial